The 33rd BVMA Symposium in Munich united Germany's clinical research community, and for entimo's CEO Marc Jantke it was his first time at what insiders call a 'class reunion.' The nickname turned out to be more accurate than he expected.

Marc describes the opening get-together as “a fantastic opportunity to connect with others and talk about industry topics and everything beyond,” an atmosphere that set the tone for the entire event. What followed on the next day was a series of carefully curated presentations and discussions. They offered both high-level regulatory overviews and practical insights from experts navigating the daily realities of clinical research in Germany and across Europe.

The symposium exceeded every expectation, both in content and in the quality of professional engagement.

One presentation in particular stood out: the talk by Dr. Jürgen Kübler (QSciCon), also the head of entimo’s supervisory board. Dr. Kübler presented perspectives on the evolving requirements for safety reporting in clinical trials, highlighting:

• How the FDA has provided guidance while still leaving important questions unresolved
• How the EMA has yet to meaningfully address the topic
  

Marc noted this contrast as a reminder of how unevenly global regulatory bodies handle fast-shifting safety expectations, a challenge that directly affects sponsors, CROs, and software providers.

The afternoon moved into a dynamic roundtable with NGOs, industry groups, and government representatives, openly discussing Germany’s competitiveness as a clinical trial location. Topics included:

• Operational bottlenecks
• The need for clearer regulatory frameworks
• Ideas for improving efficiency and global positioning
  

These conversations pointed toward a shared ambition of reinforcing Germany’s role as a major hub for clinical research in Europe.

Marc, who regularly attends conferences across the EU and internationally, sees the BVMA Symposium as unlike any other. He highlights two defining aspects:

After such a strong first experience, Marc has no doubts about returning.

The 33rd BVMA Symposium was a window into German clinical research. With open dialogue, deep technical insights, and a rare spirit of collaboration, it reinforced what many in the field already know: Germany’s clinical research ecosystem is evolving quickly, and events like BVMA are essential for ensuring that evolution is informed, collaborative, and forward-looking.

For entimo, conversations like these are part of why we stay close to the regulatory and operational realities shaping clinical research. The same questions around safety reporting gaps, cross-border inconsistency, and operational bottlenecks that Dr. Kübler and the roundtable raised are the ones our platform work is built around, from compliant clinical trial analysis to seamless collaboration between sponsors and CROs. Events like BVMA are a reminder that the solutions worth building come out of rooms like this one, not in isolation from them.

Built for Germany's clinical research realities

Contact us